New predictive approaches for ITI treatment

Haemophilia

Volumn 20, Issue SUPPL. 6, 2014, Pages 27-43

  Minno, G D ^a   Santagostino, E ^b   Pratt, K ^c   Konigs C ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anti FVIII antibodies; B cell response; F8 mutations; Immune tolerance induction therapy; T cell response; Thrombin generation assay

Indexed keywords

BLOOD CLOTTING FACTOR 8; EPITOPE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; VON WILLEBRAND FACTOR; BLOOD CLOTTING INHIBITOR; COAGULATING AGENT;

ANTIBODY TITER; B LYMPHOCYTE; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; ITALY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MUTATION; REGISTER;

B-LYMPHOCYTES; BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ITALY; MUTATION; REGISTRIES; T-LYMPHOCYTES;

EID: 84903132096     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12467     Document Type: Review

References (48)

1. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
2. Hay CR, Di Michele DM; on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
3. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13(Suppl 5): 73-7.
4. Coppola A, Di Minno MND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
5. Mariani G, Kroner B, for the Immune Tolerance Study Group. Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
6. DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
7. Lenk H. The German registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica 2000; 85: 45-7.
8. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl 1): 33-7.
9. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
10. Kreuz W, Escuriola-Ettingshausen C, Auerswald G et al. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86(Suppl. 4): 16-20.
11. Di Minno G, Coppola A. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus 2011; 9(Suppl 2): s14-20.
12. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
13. Coppola A, Margaglione M, Santagostino E et al. Predictors of success of immune tolerance induction in haemophilia A patients with high-responding inhibitors: A score from the Italian registry. Haemophilia 2012; 18 (Suppl 3):85 [Abstract].
14. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127(Suppl 3): S21-5.
15. Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88: 547-54.
16. Santagostino E, Mancuso ME, Tripodi A et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. Thromb Haemost 2010; 8: 737-43.
17. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-85.
18. Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 2013; 121: 1944-50.
19. Prescott R, Nakai H, Saenko EL et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhaemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-71.
20. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
21. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
22. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
23. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
24. Inoue T, Shima M, Takeyama M et al. Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12: 110-3.
25. Astermark J, Voorberg J, Lenk H et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
26. Salvagno GL, Astermark J, Ekman M et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
27. Pratt KP, Thompson AR. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin Rev Allergy Immunol 2009; 37: 80-95.
28. Wroblewska A, Reipert BM, Pratt KP, Voorberg J. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost 2013; 11: 47-55.
29. Ettinger RA, Papadopoulos GK, Moustakas AK, Nepom GT, Kwok WW. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1*06 alleles. J Immunol 2006; 176: 1988-98.
30. Kwok WW, Ptacek NA, Liu AW, Buckner JH. Use of class II tetramers for identification of CD4 + T cells. J Immunol Methods 2002; 268: 71-81.
31. Kwok WW, Gebe JA, Liu A et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol 2001; 22: 583-8.
32. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.
33. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 2010; 16: 44-55.
34. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-8.
35. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18(Suppl 4): 38-42.
36. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-45.
37. Hausl C, Ahmad RU, Sasgary M et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
38. Wroblewska A, van Haren SD, Herczenik E et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood 2012; 119: 5294-300.
39. Herczenik E, van Haren SD, Wroblewska A et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol 2012; 129: 501-9, e1-5.
40. Repessé Y, Dimitrov JD, Peyron I et al. Heme binds to factor VIII and inhibits its interaction with activated factor IX. J Thromb Haemost 2012; 10: 1062-71.
41. Pandey GS, Yanover C, Miller-Jenkins LM et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med 2013; 19: 1318-24.
42. Repessé Y, Peyron I, Dimitrov JD et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphism in the HMOX1 promoter. Haematologica 2013; 98: 1650-5.
43. Kessel C, Königs C, Linde R et al. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 2008; 46: 8-15.
44. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
45. van Helden PM, Kaijen PH, Mauser-Bunschoten EP, Fischer K, van den Berg HM, Voorberg J. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia 2010; 16: 892-901.
46. van Helden PM, van den Berg HM, Gouw SC et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644-52.
47. van Haren SD, Wroblewska A, Fischer K, Voorberg J, Herczenik E. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Rev 2012; 26: 43-9.
48. Klintman J1, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol 2013; 163: 385-92.